ExpreS2ion to participate in upcoming events

Hørsholm, Denmark, 12 October 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include the World Vaccine Congress Europe (16-19 October) and the Conference on Vaccines Research & Development (6-8 November).

By attending relevant industry and investor events, the company aims to increase the awareness of its technology platform and its exciting development pipeline. More information on each event and how to register is found below and on the Company’s website.

16-19 October 2023 | World Vaccine Congress Europe
Barcelona, Spain (In-person and virtual)
Dr Farshad Guirakhoo, Chief Scientific Officer, presents as invited speaker. Presentation title: “Preclinical proof of concept for a novel VLP-based vaccine candidate for treatment of HER2+ breast cancers.”

More about the event at: https://www.terrapinn.com/conference/world-vaccine-congress-europe

• Speaker list | Vaccine Congress Europe (terrapinn.com)
• Farshad Guirakhoo | Vaccine Congress Europe (terrapinn.com)

6-8 November 2023 | Conference on Vaccines Research & Development
Baltimore, Maryland, USA (In-person and virtual)
Dr Farshad Guirakhoo, Chief Scientific Officer, presents as invited speaker and will attend (virtually) Baltimore, MS, MA and present. Presentation title: “Preclinical proof of concept for a novel VLP-based vaccine candidate for treatment of HER2+ breast cancers“.

More about the event at: Vaccines Research & Development Conference | Vaccines Conferences | Vaccines R&D (unitedscientificgroup.org)

• Speakers | Vaccines Conferences 2023 | Vaccines R&D 2023 (unitedscientificgroup.org)

Certified Adviser
Svensk Kapitalmarknadsgranskning AB

For further information about ExpreS²ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
E-mail: investor@expres2ionbio.com 

About ExpreS2ion
ExpreS²ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS²ion Biotech Holding AB with company register number 559033-3729. ExpreS²ion has developed a unique technology platform, ExpreS², for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS² is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS²ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS²ion owns 34%. For additional information, please visit www.expres2ionbio.com.